While the reported outcomes were controversial, FDA has recently approved two selective RET inhibitors (pralsetinib and selpercatinib) as therapeutic options for metastatic NSCLC patients harboring RET fusions [114, 115]. This evidence concerns the gene RET and non-small cell lung carcinoma.